Prof. Lisa Licitra: “Truly pursuing precision medicine means pushing the boundaries of patient selection using molecular biology and artificial intelligence on all big data, not just molecular information”
Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei
Investigations are time-consuming and expensive, so greater public funding is needed, according to Prof. George Coukos
Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women
New insights into breast cancer immunology and genomics support further segmentation of patient subgroups and treatment approaches, says Prof. Sherene Loi
At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon
With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments
This year’s recipient of the TAT Honorary Award Prof. Ruth Plummer, retraces the most significant milestones of her career in early phase studies
Despite some share the concern of having their career plans delayed or disrupted by the pandemic, the new challenges emerged in these unprecedented times represent a unique opportunity to grow-up as oncology professionals and get ready to a new scenario where team working, humanisation of care and virtual education will be more crucial than ever.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.